bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program Read more about bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program
BofA Securities Health Care Conference 2020 Read more about BofA Securities Health Care Conference 2020
bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event Read more about bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA Read more about Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development Read more about bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development
bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress
bluebird bio Announces Upcoming Investor Events Read more about bluebird bio Announces Upcoming Investor Events
bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β⁰/β0 Genotype Read more about bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β⁰/β0 Genotype
bluebird bio Announces Investor Events in January Read more about bluebird bio Announces Investor Events in January
bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition Read more about bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition